Everyone’s Buying ‘Glucose’ Wearables in 2026 — Here’s the One Thing the Numbers Don’t Tell You (and the New Rule Change That’s Fueling the Hype)
OTC clearance turned CGMs into a retail wellness gadget—but it also widened the gap between measurement and meaning. The stream of “spikes” looks authoritative; in healthy people, context is the real data.
Key Points
- 1Track the real catalyst: FDA OTC clearances in 2024 turned CGMs from prescription diabetes tools into retail wellness wearables.
- 2Understand the blind spot: CGMs measure interstitial fluid with lag, noise, and artifacts—numbers feel definitive even when context is missing.
- 3Use guardrails, not guilt: run a time-limited experiment, log meals/sleep/stress, and stop if the data turns eating into moral judgment.
A few years ago, wearing a continuous glucose monitor (CGM) without diabetes would have looked like an affectation—or a medical mix-up. In 2026, it looks increasingly like a consumer choice. You can buy a sensor the way you buy a heart-rate strap: to learn how your body responds to food, exercise, sleep, and stress.
The shift isn’t just cultural. It’s regulatory. In the U.S., the Food and Drug Administration opened a new door in 2024 by clearing the first over-the-counter CGM, then clearing two more systems designed for nonprescription access. A device category once controlled by prescriptions and insurance codes now sits closer to the retail shelf.
That change has created a predictable second-order effect: data without interpretation. CGMs generate a hypnotic stream of numbers—peaks, dips, and slopes that seem to tell a story about discipline and health. For many people without diabetes, the hard part isn’t getting the data anymore. The hard part is knowing what it means, what it doesn’t mean, and what to do with it without turning everyday eating into a moral referendum.
“OTC CGMs didn’t just widen access. They widened the gap between measurement and meaning.”
— — TheMurrow Editorial
The 2024 FDA decisions that turned CGMs into a wellness product
On March 5, 2024, the FDA cleared Dexcom Stelo as the first over-the-counter (OTC) continuous glucose monitor in the U.S. The FDA described Stelo as intended for adults 18+ who do not use insulin, including people without diabetes who want to understand how diet and exercise affect glucose. The agency also stressed limits: Stelo is not for people with problematic hypoglycemia and is not designed to alert users to dangerous lows. (FDA press announcement, March 5, 2024)
Three months later, on June 10, 2024, the FDA cleared two OTC Abbott systems: Lingo, marketed for wellness and lifestyle use, and Libre Rio, intended for adults with type 2 diabetes not using insulin. (CNBC, June 10, 2024)
By September 5, 2024, Abbott announced Lingo availability in the U.S., priced like a consumer wearable: $49 for one sensor, $89 for two, and $249 for six, according to CNBC reporting. Those numbers matter because they signal who the new market is for—people who can buy a sensor on a whim, try it for a month, then decide whether the insights justify the cost.
OTC access isn’t just convenience—it changes the audience
A parallel trend has also made CGMs more visible in clinical care: Medicare expanded CGM coverage criteria in April 2023, easing some barriers and aligning more closely with ADA standards, as described by the American Academy of Family Physicians. But the OTC hype is not primarily a Medicare story. It’s a retail story, made possible by the FDA’s willingness to let adults buy and use CGMs without the involvement of a health care provider.
“The inflection point wasn’t an influencer. It was a clearance letter.”
— — TheMurrow Editorial
What a CGM actually measures—and why the “blood sugar” label misleads
CGMs generally measure glucose in interstitial fluid—the fluid between cells—not the glucose in blood drawn from a vein or fingerstick. The difference is more than technical. It changes how you should read the graph, especially when glucose is moving quickly after meals or during intense exercise. (GSSI sports science review)
Lag is real, especially when you’re chasing spikes
That means a CGM can be “right” and still feel wrong. If you eat, sprint for a train, or lift heavy, the line on your phone may be describing where your glucose was minutes ago—not where it is now.
Accuracy depends on context, not just the brand
The real-world caveat list is longer than most marketing implies. Sports-science literature also flags factors that can distort readings, including:
- Compression lows (pressure on the sensor, often during sleep)
- Some medications
- High vitamin C
- Hydration status
None of these issues make CGMs “bad.” They make CGMs human: a sophisticated estimate running through messy biology.
“A CGM readout is a model of glucose dynamics—not a courtroom verdict.”
— — TheMurrow Editorial
The new rule change fueling the hype: access without a clinician
The FDA’s language around Stelo signaled exactly how the agency sees this new lane: an OTC CGM expands access “without the involvement of a health care provider,” for adults who do not use insulin—including people without diabetes who want to understand diet and exercise effects. That framing is powerful: it validates curiosity.
At the same time, the FDA put guardrails in plain English. Stelo is not for people with problematic hypoglycemia and not designed to alert users to dangerous lows. Those are not footnotes. They are reminders that OTC does not equal medical-grade protection for every scenario.
What OTC clearance does *not* mean
- “If I can measure it, I can control it.” Sometimes true. Often overstated.
- “If it spikes, it’s bad.” Not necessarily—especially in people without diabetes.
- “If it doesn’t spike, it’s healthy.” A low-variability diet can still be nutritionally poor.
OTC access is a catalyst. It is not a clinical consensus about what “good” glucose patterns look like for non-diabetics, or how those patterns translate into long-term outcomes.
Key Insight
Interpreting “spikes” in healthy people: the missing context
A CGM can show patterns. It usually cannot prove causality. It cannot tell you whether a rise after lunch reflects the food itself, the prior night’s sleep, the timing of exercise, stress hormones, or where you are in the day’s normal rhythms.
Case study: the salad that “spikes” and the workout that “fixes” it
What’s true: movement often changes glucose dynamics, and CGMs can make that visible in a way that feels motivating.
What’s unclear: whether that specific spike was harmful, whether the “fixed” graph is meaningfully better for long-term health, and whether the person is now sliding into a pattern of compensatory behavior—walking not for fitness or pleasure, but to erase a number.
The danger of flattening everything
A practical way to keep perspective: treat CGM outputs as signals to explore, not scores to obey. A signal can prompt questions—meal composition, timing, stress, sleep, hydration. A score encourages punishment and restriction.
A useful mental switch
The performance crowd vs. the metabolic-anxiety crowd
The performance mindset: glucose as training feedback
For these users, a short-term CGM “cycle” might answer questions like:
- Does my pre-workout meal keep energy steady?
- Do I crash mid-session if I delay carbs?
- How does sleep affect morning glucose response?
The outputs are actionable, but the interpretation is tethered to performance outcomes and training logs.
The anxiety mindset: glucose as moral judgment
OTC availability increases the odds that people with no clinical need will interpret normal variation as pathology. That does not make them foolish. It makes them human in a culture that confuses quantification with certainty.
Two ways people use OTC CGMs
Before
- Performance mindset
- glucose as training feedback
- interpretation tied to fueling and recovery
- tool not diagnosis
After
- Anxiety mindset
- glucose as moral score
- spikes as threats
- normal variation read as pathology
How to use a CGM intelligently (and when not to use one)
Practical takeaways for first-time OTC CGM users
- Run a time-limited experiment. Two weeks can show patterns without turning your life into a permanent lab.
- Pair CGM data with a log. Write down meal timing, sleep, exercise, and stress. The graph alone is context-free.
- Focus on patterns, not single peaks. Interstitial lag and day-to-day variability make one-off “events” easy to misread.
- Watch for artifacts. Compression lows during sleep and exercise-related inaccuracies can create phantom narratives.
- Resist absolutism. A change that reduces a spike is not automatically “healthier,” especially if it reduces fiber, variety, or caloric adequacy.
Guardrails for a first CGM experiment
- ✓Run a time-limited experiment (e.g., two weeks)
- ✓Pair CGM data with a log (meals, sleep, exercise, stress)
- ✓Focus on patterns, not single peaks
- ✓Watch for artifacts (compression lows, exercise inaccuracies)
- ✓Resist absolutism (lower spike doesn’t automatically mean healthier)
When an OTC CGM is a bad idea
People with a tendency toward obsessive tracking, disordered eating, or health anxiety should also be cautious. A device that streams numbers all day is not neutral; it changes behavior. Sometimes for the better. Sometimes not.
Editor's Note
The bigger picture: measurement is cheap; interpretation is the scarce resource
Yet the most crucial element is missing from the checkout flow: interpretive standards for people without diabetes. Medicine has decades of clinical context for diagnosing and treating diabetes. Wellness CGM users sit in a newer, fuzzier territory where numbers arrive faster than consensus.
OTC clearance changed what’s possible in the consumer market. It did not change what physiology is allowed to do. Glucose rises after meals. Glucose moves during exercise. Interstitial sensors lag. Real bodies vary across days.
Use the device if it helps you learn. Put it away if it makes you afraid of lunch.
Frequently Asked Questions
What was the major FDA change that made CGMs a wellness product?
The key change was the FDA clearing over-the-counter CGMs. On March 5, 2024, the FDA cleared Dexcom Stelo as the first OTC CGM in the U.S., intended for adults 18+ who do not use insulin, including people without diabetes interested in diet/exercise effects. On June 10, 2024, the FDA cleared Abbott Lingo (wellness) and Libre Rio (type 2 diabetes, not using insulin).
How much do OTC CGMs cost?
Pricing varies by brand and package. Abbott’s Lingo was reported by CNBC to be priced at $49 for one sensor, $89 for two sensors, and $249 for six sensors when it became available in the U.S. in September 2024. These price points resemble consumer wearables more than traditional prescription medical devices, which is part of why adoption has broadened.
Do CGMs measure blood glucose directly?
Most CGMs measure glucose in interstitial fluid, not directly in blood. That distinction matters because interstitial readings can lag behind blood glucose, especially when glucose is changing quickly—after meals or during intense exercise. Research often cites a physiologic delay of around ~5–10 minutes, with the potential for additional display lag due to sensor processing.
Are CGMs accurate for people without diabetes?
Evidence suggests accuracy can be “acceptable” in non-diabetic contexts, but it is context-dependent. A sports-science review of CGM use in athletes without diabetes notes accuracy can be worse during exercise, and mentions performance metrics such as MARD that can be <15% in some exercising contexts. External factors—like compression lows, certain medications, high vitamin C, and hydration status—can distort readings.
Should I worry about every glucose spike if I don’t have diabetes?
Not automatically. A CGM can show you that glucose rises after meals, but it often cannot tell you what that rise means for long-term health in someone without diabetes. Interstitial lag, sensor noise, and day-to-day variability also make single spikes easy to over-interpret. Many users do better focusing on repeatable patterns and overall habits rather than trying to flatten every rise.
Who should avoid OTC CGMs?
The FDA stated Dexcom Stelo is not for people with problematic hypoglycemia and not designed to alert users to dangerous lows. Anyone concerned about low blood sugar episodes should seek clinical guidance rather than relying on an OTC sensor. People prone to obsessive tracking or disordered eating patterns should also be cautious; always-on numbers can intensify anxiety and rigid food rules.
